Lindbrook Capital LLC Sells 91 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Lindbrook Capital LLC decreased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,718 shares of the medical research company’s stock after selling 91 shares during the period. Lindbrook Capital LLC’s holdings in Thermo Fisher Scientific were worth $4,015,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Legacy Investment Solutions LLC bought a new position in shares of Thermo Fisher Scientific in the 3rd quarter valued at about $26,000. Peterson Financial Group Inc. bought a new position in Thermo Fisher Scientific during the third quarter worth about $27,000. Barrett & Company Inc. bought a new position in Thermo Fisher Scientific during the fourth quarter worth about $28,000. FPC Investment Advisory Inc. bought a new position in Thermo Fisher Scientific during the fourth quarter worth about $28,000. Finally, Missouri Trust & Investment Co bought a new position in Thermo Fisher Scientific during the fourth quarter worth about $29,000. Institutional investors own 89.23% of the company’s stock.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CFO Stephen Williamson sold 9,825 shares of the company’s stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total transaction of $5,753,421.75. Following the sale, the chief financial officer now owns 27,296 shares of the company’s stock, valued at approximately $15,984,264.64. This represents a 26.47 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total transaction of $175,677.00. Following the sale, the executive vice president now directly owns 16,363 shares in the company, valued at $9,582,009.17. This trade represents a 1.80 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.34% of the company’s stock.

Wall Street Analysts Forecast Growth

TMO has been the subject of a number of research analyst reports. Morgan Stanley lifted their price target on Thermo Fisher Scientific from $647.00 to $678.00 and gave the stock an “overweight” rating in a report on Friday, January 31st. Sanford C. Bernstein upgraded Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 price target for the company in a report on Friday, January 10th. Wells Fargo & Company lifted their price target on Thermo Fisher Scientific from $660.00 to $680.00 and gave the stock an “overweight” rating in a report on Friday, January 31st. Citigroup reduced their price objective on Thermo Fisher Scientific from $650.00 to $570.00 and set a “neutral” rating for the company in a report on Tuesday. Finally, Scotiabank boosted their price objective on Thermo Fisher Scientific from $605.00 to $650.00 and gave the stock a “sector perform” rating in a report on Monday, February 3rd. Four investment analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company’s stock. According to MarketBeat, Thermo Fisher Scientific has an average rating of “Moderate Buy” and an average price target of $653.23.

Thermo Fisher Scientific Stock Up 1.6 %

Shares of TMO opened at $524.63 on Thursday. The firm has a 50 day simple moving average of $548.99 and a two-hundred day simple moving average of $563.46. The company has a market cap of $197.92 billion, a P/E ratio of 31.74, a P/E/G ratio of 2.99 and a beta of 0.77. Thermo Fisher Scientific Inc. has a one year low of $493.30 and a one year high of $627.88. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, topping analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. Research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific declared that its Board of Directors has authorized a stock repurchase plan on Friday, November 15th that authorizes the company to buyback $4.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to reacquire up to 2% of its stock through open market purchases. Stock buyback plans are usually a sign that the company’s management believes its shares are undervalued.

Thermo Fisher Scientific Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 15th. Investors of record on Friday, March 14th will be paid a $0.43 dividend. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Friday, March 14th. This represents a $1.72 annualized dividend and a dividend yield of 0.33%. Thermo Fisher Scientific’s payout ratio is currently 10.41%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.